Genetics of Pulmonary Arterial Hypertension

 

 Buy Article Permissions and Reprints

ABSTRACT

Tremendous progress has been made in understanding the genetics of hereditable pulmonary arterial hypertension (HPAH) since its description in the 1950s. Germline mutations in the gene coding bone morphogenetic receptor type 2 (BMPR2) are detectable in the majority of cases of HPAH, and in a small proportion of cases of idiopathic pulmonary arterial hypertension (IPAH). HPAH is an autosomal dominant disease characterized by reduced penetrance, variable expressivity, female predominance, and genetic anticipation. These characteristics suggest that endogenous and exogenous factors modify disease expression and areas of emphasis for future investigation. The variable clinical expression makes genetic counseling complex because the majority of carriers of a BMPR2 mutation will not be diagnosed with the disease. This issue will become increasingly important, as clinical testing for BMPR2 mutations is now available for the evaluation of patients and family members with HPAH and IPAH.

REFERENCES

• 1 Dresdale D T, Schultz M, Michtom R J. Primary pulmonary hypertension, I: Clinical and hemodynamic study.  Am J Med. 1951;  11 686-705
  CrossrefPubMedGoogle Scholar
• 2 Dresdale D T, Michtom R J, Schultz M. Recent studies in primary pulmonary hypertension, including pharmacodynamic observations on pulmonary vascular resistance.  Bull N Y Acad Med. 1954;  30 195-207
  PubMedGoogle Scholar
• 3 Machado R, Chung W, Eickelberg O et al.. Genetics and genomics of pulmonary arterial hypertension.  J Am Coll Cardiol. , In press
  PubMedGoogle Scholar
• 4 Loyd J E, Primm R K, Newman J H. Familial primary pulmonary hypertension: clinical patterns.  Am Rev Respir Dis. 1984;  129 194-197
  PubMedGoogle Scholar
• 5 Thomas A Q, Gaddipati R, Newman J H, Loyd J E. Genetics of primary pulmonary hypertension.  Clin Chest Med. 2001;  22 477-491 , ix
  CrossrefPubMedGoogle Scholar
• 6 Thomson J R, Machado R D, Pauciulo M W et al.. Sporadic primary pulmonary hypertension is associated with germline mutations of the gene encoding BMPR-II, a receptor member of the TGF-beta family.  J Med Genet. 2000;  37 741-745
  CrossrefPubMedGoogle Scholar
• 7 Loyd J E, Butler M G, Foroud T M, Conneally P M, Phillips III J A, Newman J H. Genetic anticipation and abnormal gender ratio at birth in familial primary pulmonary hypertension.  Am J Respir Crit Care Med. 1995;  152 93-97
  CrossrefPubMedGoogle Scholar
• 8 Rich S, Dantzker D R, Ayres S M et al.. Primary pulmonary hypertension: a national prospective study.  Ann Intern Med. 1987;  107 216-223
  CrossrefPubMedGoogle Scholar
• 9 Nichols W C, Koller D L, Slovis B et al.. Localization of the gene for familial primary pulmonary hypertension to chromosome 2q31-32.  Nat Genet. 1997;  15 277-280
  CrossrefPubMedGoogle Scholar
• 10 Morse J H, Barst R J. Detection of familial primary pulmonary hypertension by genetic testing.  N Engl J Med. 1997;  337 202-203
  CrossrefPubMedGoogle Scholar
• 11 Lane K B, Machado R D, Pauciulo M W The International PPH Consortium et al. Heterozygous germline mutations in BMPR2, encoding a TGF-beta receptor, cause familial primary pulmonary hypertension.  Nat Genet. 2000;  26 81-84
  CrossrefPubMedGoogle Scholar
• 12 Deng Z, Morse J H, Slager S L et al.. Familial primary pulmonary hypertension (gene PPH1) is caused by mutations in the bone morphogenetic protein receptor-II gene.  Am J Hum Genet. 2000;  67 737-744
  CrossrefPubMedGoogle Scholar
• 13 Newman J H, Phillips III J A, Loyd J E. Narrative review: the enigma of pulmonary arterial hypertension: new insights from genetic studies.  Ann Intern Med. 2008;  148 278-283
  CrossrefPubMedGoogle Scholar
• 14 Sztrymf B, Yaïci A, Girerd B, Humbert M. Genes and pulmonary arterial hypertension.  Respiration. 2007;  74 123-132
  CrossrefPubMedGoogle Scholar
• 15 Newman J H, Trembath R C, Morse J A et al.. Genetic basis of pulmonary arterial hypertension: current understanding and future directions.  J Am Coll Cardiol. 2004;  43(12, Suppl S) 33S-39S
  CrossrefPubMedGoogle Scholar
• 16 Gaine S P, Rubin L J. Primary pulmonary hypertension.  Lancet. 1998;  352 719-725
  CrossrefPubMedGoogle Scholar
• 17 Machado R D, James V, Southwood M et al.. Investigation of second genetic hits at the BMPR2 locus as a modulator of disease progression in familial pulmonary arterial hypertension.  Circulation. 2005;  111 607-613
  CrossrefPubMedGoogle Scholar
• 18 Irey N S, Manion W C, Taylor H B. Vascular lesions in women taking oral contraceptives.  Arch Pathol. 1970;  89 1-8
  PubMedGoogle Scholar
• 19 Irey N S, Norris H J. Intimal vascular lesions associated with female reproductive steroids.  Arch Pathol. 1973;  96 227-234
  PubMedGoogle Scholar
• 20 Kleiger R E, Boxer M, Ingham R E, Harrison D C. Pulmonary hypertension in patients using oral contraceptives. A report of six cases.  Chest. 1976;  69 143-147
  CrossrefPubMedGoogle Scholar
• 21 Morse J H, Horn E M, Barst R J. Hormone replacement therapy: a possible risk factor in carriers of familial primary pulmonary hypertension.  Chest. 1999;  116 847
  CrossrefPubMedGoogle Scholar
• 22 Runo J R, Loyd J E. Primary pulmonary hypertension.  Lancet. 2003;  361 1533-1544
  CrossrefPubMedGoogle Scholar
• 23 Sztrymf B, Coulet F, Girerd B et al.. Clinical outcomes of pulmonary arterial hypertension in carriers of BMPR2 mutation.  Am J Respir Crit Care Med. 2008;  177 1377-1383
  CrossrefPubMedGoogle Scholar
• 24 Elliott C G, Glissmeyer E W, Havlena G T et al.. Relationship of BMPR2 mutations to vasoreactivity in pulmonary arterial hypertension.  Circulation. 2006;  113 2509-2515
  CrossrefPubMedGoogle Scholar
• 25 Montani D, Marcelin A G, Sitbon O, Calvez V, Simonneau G, Humbert M. Human herpes virus 8 in HIV and non-HIV infected patients with pulmonary arterial hypertension in France.  AIDS. 2005;  19 1239-1240
  CrossrefPubMedGoogle Scholar
• 26 Archer S L, Michelakis E D. An evidence-based approach to the management of pulmonary arterial hypertension.  Curr Opin Cardiol. 2006;  21 385-392
  CrossrefPubMedGoogle Scholar
• 27 Rosenzweig E B, Morse J H, Knowles J A et al.. Clinical implications of determining BMPR2 mutation status in a large cohort of children and adults with pulmonary arterial hypertension.  J Heart Lung Transplant. 2008;  27 668-674
  CrossrefPubMedGoogle Scholar
• 28 Sztrymf B, Yaici A, Jaïs X, Simonneau G, Sitbon O, Humbert M. Genetics of pulmonary arterial hypertension: recent data and practical applications [in French].  Rev Mal Respir. 2005;  22(5 Pt 1) 796-805
  CrossrefPubMedGoogle Scholar
• 29 Pearson C E, Nichol Edamura K, Cleary J D. Repeat instability: mechanisms of dynamic mutations.  Nat Rev Genet. 2005;  6 729-742
  CrossrefPubMedGoogle Scholar
• 30 Armanios M, Chen J L, Chang Y P et al.. Haploinsufficiency of telomerase reverse transcriptase leads to anticipation in autosomal dominant dyskeratosis congenita.  Proc Natl Acad Sci U S A. 2005;  102 15960-15964
  CrossrefPubMedGoogle Scholar
• 31 Newman J H. Pulmonary hypertension.  Am J Respir Crit Care Med. 2005;  172 1072-1077
  CrossrefPubMedGoogle Scholar
• 32 Morse J H, Jones A C, Barst R J, Hodge S E, Wilhelmsen K C, Nygaard T G. Familial primary pulmonary hypertension locus mapped to chromosome 2q31-q32.  Chest. 1998;  114(1, Suppl) 57S-58S
  CrossrefPubMedGoogle Scholar
• 33 Morse J H, Jones A C, Barst R J, Hodge S E, Wilhelmsen K C, Nygaard T G. Mapping of familial primary pulmonary hypertension locus (PPH1) to chromosome 2q31-q32.  Circulation. 1997;  95 2603-2606
  CrossrefPubMedGoogle Scholar
• 34 Machado R D, Aldred M A, James V et al.. Mutations of the TGF-beta type II receptor BMPR2 in pulmonary arterial hypertension.  Hum Mutat. 2006;  27 121-132
  CrossrefPubMedGoogle Scholar
• 35 Johnson D W, Berg J N, Baldwin M A et al.. Mutations in the activin receptor-like kinase 1 gene in hereditary haemorrhagic telangiectasia type 2.  Nat Genet. 1996;  13 189-195
  CrossrefPubMedGoogle Scholar
• 36 McAllister K A, Grogg K M, Johnson D W et al.. Endoglin, a TGF-beta binding protein of endothelial cells, is the gene for hereditary haemorrhagic telangiectasia type 1.  Nat Genet. 1994;  8 345-351
  CrossrefPubMedGoogle Scholar
• 37 Harrison R E, Flanagan J A, Sankelo M et al.. Molecular and functional analysis identifies ALK-1 as the predominant cause of pulmonary hypertension related to hereditary haemorrhagic telangiectasia.  J Med Genet. 2003;  40 865-871
  CrossrefPubMedGoogle Scholar
• 38 Trembath R C, Thomson J R, Machado R D et al.. Clinical and molecular genetic features of pulmonary hypertension in patients with hereditary hemorrhagic telangiectasia.  N Engl J Med. 2001;  345 325-334
  CrossrefPubMedGoogle Scholar
• 39 Chaouat A, Coulet F, Favre C et al.. Endoglin germline mutation in a patient with hereditary haemorrhagic telangiectasia and dexfenfluramine associated pulmonary arterial hypertension.  Thorax. 2004;  59 446-448
  CrossrefPubMedGoogle Scholar
• 40 Harrison R E, Berger R, Haworth S G et al.. Transforming growth factor-beta receptor mutations and pulmonary arterial hypertension in childhood.  Circulation. 2005;  111 435-441
  CrossrefPubMedGoogle Scholar
• 41 Shi Y, Massagué J. Mechanisms of TGF-beta signaling from cell membrane to the nucleus.  Cell. 2003;  113 685-700
  CrossrefPubMedGoogle Scholar
• 42 Fernández-L A, Sanz-Rodriguez F, Blanco F J, Bernabéu C, Botella L M. Hereditary hemorrhagic telangiectasia, a vascular dysplasia affecting the TGF-beta signaling pathway.  Clin Med Res. 2006;  4 66-78
  CrossrefPubMedGoogle Scholar
• 43 De Caestecker M, Meyrick B. Bone morphogenetic proteins, genetics and the pathophysiology of primary pulmonary hypertension.  Respir Res. 2001;  2 193-197
  CrossrefPubMedGoogle Scholar
• 44 Derynck R, Zhang Y E. Smad-dependent and Smad-independent pathways in TGF-beta family signalling.  Nature. 2003;  425 577-584
  CrossrefPubMedGoogle Scholar
• 45 Davies R J, Morrell N W. Molecular mechanisms of pulmonary arterial hypertension: role of mutations in the bone morphogenetic protein type II receptor.  Chest. 2008;  134 1271-1277
  CrossrefPubMedGoogle Scholar
• 46 Yang X, Long L, Southwood M et al.. Dysfunctional Smad signaling contributes to abnormal smooth muscle cell proliferation in familial pulmonary arterial hypertension.  Circ Res. 2005;  96 1053-1063
  CrossrefPubMedGoogle Scholar
• 47 Perros F, Dorfmüller P, Humbert M. Current insights on the pathogenesis of pulmonary arterial hypertension.  Semin Respir Crit Care Med. 2005;  26 355-364
  Article in Thieme ConnectPubMedGoogle Scholar
• 48 Said S I. Mediators and modulators of pulmonary arterial hypertension.  Am J Physiol Lung Cell Mol Physiol. 2006;  291 L547-L548
  CrossrefPubMedGoogle Scholar
• 49 Scharpfenecker M, van Dinther M, Liu Z et al.. BMP-9 signals via ALK1 and inhibits bFGF-induced endothelial cell proliferation and VEGF-stimulated angiogenesis.  J Cell Sci. 2007;  120(Pt 6) 964-972
  CrossrefPubMedGoogle Scholar
• 50 Eddahibi S, Humbert M, Sediame S et al.. Imbalance between platelet vascular endothelial growth factor and platelet-derived growth factor in pulmonary hypertension: effect of prostacyclin therapy.  Am J Respir Crit Care Med. 2000;  162(4 Pt 1) 1493-1499
  PubMedGoogle Scholar
• 51 Hansmann G, Wagner R A, Schellong S et al.. Pulmonary arterial hypertension is linked to insulin resistance and reversed by peroxisome proliferator-activated receptor-gamma activation.  Circulation. 2007;  115 1275-1284
  PubMedGoogle Scholar
• 52 Machado R D, Pauciulo M W, Thomson J R et al.. BMPR2 haploinsufficiency as the inherited molecular mechanism for primary pulmonary hypertension.  Am J Hum Genet. 2001;  68 92-102
  CrossrefPubMedGoogle Scholar
• 53 Koehler R, Grünig E, Pauciulo M W et al.. Low frequency of BMPR2 mutations in a German cohort of patients with sporadic idiopathic pulmonary arterial hypertension.  J Med Genet. 2004;  41 e127
  CrossrefPubMedGoogle Scholar
• 54 Morisaki H, Nakanishi N, Kyotani S, Takashima A, Tomoike H, Morisaki T. BMPR2 mutations found in Japanese patients with familial and sporadic primary pulmonary hypertension.  Hum Mutat. 2004;  23 632
  PubMedGoogle Scholar
• 55 Elliott C G. Genetics of pulmonary arterial hypertension: current and future implications.  Semin Respir Crit Care Med. 2005;  26 365-371
  Article in Thieme ConnectPubMedGoogle Scholar
• 56 Cogan J D, Pauciulo M W, Batchman A P et al.. High frequency of BMPR2 exonic deletions/duplications in familial pulmonary arterial hypertension.  Am J Respir Crit Care Med. 2006;  174 590-598
  CrossrefPubMedGoogle Scholar
• 57 Aldred M A, Vijayakrishnan J, James V et al.. BMPR2 gene rearrangements account for a significant proportion of mutations in familial and idiopathic pulmonary arterial hypertension.  Hum Mutat. 2006;  27 212-213
  PubMedGoogle Scholar
• 58 Fujiwara M, Yagi H, Matsuoka R et al.. Implications of mutations of activin receptor-like kinase 1 gene (ALK1) in addition to bone morphogenetic protein receptor II gene (BMPR2) in children with pulmonary arterial hypertension.  Circ J. 2008;  72 127-133
  CrossrefPubMedGoogle Scholar
• 59 Rudarakanchana N, Flanagan J A, Chen H et al.. Functional analysis of bone morphogenetic protein type II receptor mutations underlying primary pulmonary hypertension.  Hum Mol Genet. 2002;  11 1517-1525
  CrossrefPubMedGoogle Scholar
• 60 Nishihara A, Watabe T, Imamura T, Miyazono K. Functional heterogeneity of bone morphogenetic protein receptor-II mutants found in patients with primary pulmonary hypertension.  Mol Biol Cell. 2002;  13 3055-3063
  CrossrefPubMedGoogle Scholar
• 61 Khajavi M, Inoue K, Lupski J R. Nonsense-mediated mRNA decay modulates clinical outcome of genetic disease.  Eur J Hum Genet. 2006;  14 1074-1081
  CrossrefPubMedGoogle Scholar
• 62 Noensie E N, Dietz H C. A strategy for disease gene identification through nonsense-mediated mRNA decay inhibition.  Nat Biotechnol. 2001;  19 434-439
  PubMedGoogle Scholar
• 63 Kuzmiak H A, Maquat L E. Applying nonsense-mediated mRNA decay research to the clinic: progress and challenges.  Trends Mol Med. 2006;  12 306-316
  CrossrefPubMedGoogle Scholar
• 64 Humbert M, Deng Z, Simonneau G et al.. BMPR2 germline mutations in pulmonary hypertension associated with fenfluramine derivatives.  Eur Respir J. 2002;  20 518-523
  CrossrefPubMedGoogle Scholar
• 65 Phillips III J A, Poling J S, Phillips C A et al.. Synergistic heterozygosity for TGFbeta1 SNPs and BMPR2 mutations modulates the age at diagnosis and penetrance of familial pulmonary arterial hypertension.  Genet Med. 2008;  10 359-365
  CrossrefPubMedGoogle Scholar
• 66 Hamid R, Cogan J D, Austin E D et al.. Penetrance of pulmonary arterial hypertension is modulated by the expression of normal BMPR2 allele.  Hum Mutat. 2009;  30 649-654
  CrossrefPubMedGoogle Scholar
• 67 Atkinson C, Stewart S, Upton P D et al.. Primary pulmonary hypertension is associated with reduced pulmonary vascular expression of type II bone morphogenetic protein receptor.  Circulation. 2002;  105 1672-1678
  CrossrefPubMedGoogle Scholar
• 68 Abraham W T, Raynolds M V, Badesch D B et al.. Angiotensin-converting enzyme DD genotype in patients with primary pulmonary hypertension: increased frequency and association with preserved haemodynamics.  J Renin Angiotensin Aldosterone Syst. 2003;  4 27-30
  CrossrefPubMedGoogle Scholar
• 69 Hoeper M M, Tacacs A, Stellmacher U, Lichtinghagen R. Lack of association between angiotensin converting enzyme (ACE) genotype, serum ACE activity, and haemodynamics in patients with primary pulmonary hypertension.  Heart. 2003;  89 445-446
  CrossrefPubMedGoogle Scholar
• 70 Koehler R, Olschewski H, Hoeper M, Janssen B, Grünig E. Serotonin transporter gene polymorphism in a cohort of German patients with idiopathic pulmonary arterial hypertension or chronic thromboembolic pulmonary hypertension.  Chest. 2005;  128(6, Suppl) 619S
  PubMedGoogle Scholar
• 71 Machado R D, Koehler R, Glissmeyer E et al.. Genetic association of the serotonin transporter in pulmonary arterial hypertension.  Am J Respir Crit Care Med. 2006;  173 793-797
  CrossrefPubMedGoogle Scholar
• 72 Willers E D, Newman J H, Loyd J E et al.. Serotonin transporter polymorphisms in familial and idiopathic pulmonary arterial hypertension.  Am J Respir Crit Care Med. 2006;  173 798-802
  CrossrefPubMedGoogle Scholar
• 73 Remillard C V, Tigno D D, Platoshyn O et al.. Function of Kv1.5 channels and genetic variations of KCNA5 in patients with idiopathic pulmonary arterial hypertension.  Am J Physiol Cell Physiol. 2007;  292 C1837-C1853
  CrossrefPubMedGoogle Scholar
• 74 Lee S L, Wang W W, Moore B J, Fanburg B L. Dual effect of serotonin on growth of bovine pulmonary artery smooth muscle cells in culture.  Circ Res. 1991;  68 1362-1368
  PubMedGoogle Scholar
• 75 Liu Y, Suzuki Y J, Day R M, Fanburg B L. Rho kinase-induced nuclear translocation of ERK1/ERK2 in smooth muscle cell mitogenesis caused by serotonin.  Circ Res. 2004;  95 579-586
  CrossrefPubMedGoogle Scholar
• 76 Lee S L, Wang W W, Finlay G A, Fanburg B L. Serotonin stimulates mitogen-activated protein kinase activity through the formation of superoxide anion.  Am J Physiol. 1999;  277(2 Pt 1) L282-L291
  PubMedGoogle Scholar
• 77 Hervé P, Launay J M, Scrobohaci M L et al.. Increased plasma serotonin in primary pulmonary hypertension.  Am J Med. 1995;  99 249-254
  CrossrefPubMedGoogle Scholar
• 78 Eddahibi S, Humbert M, Fadel E et al.. Serotonin transporter overexpression is responsible for pulmonary artery smooth muscle hyperplasia in primary pulmonary hypertension.  J Clin Invest. 2001;  108 1141-1150
  CrossrefPubMedGoogle Scholar
• 79 Morrell N W. Pulmonary hypertension due to BMPR2 mutation: a new paradigm for tissue remodeling?.  Proc Am Thorac Soc. 2006;  3 680-686
  CrossrefPubMedGoogle Scholar
• 80 Morrell N W, Yang X, Upton P D et al.. Altered growth responses of pulmonary artery smooth muscle cells from patients with primary pulmonary hypertension to transforming growth factor-beta(1) and bone morphogenetic proteins.  Circulation. 2001;  104 790-795
  CrossrefPubMedGoogle Scholar
• 81 Zaiman A L, Podowski M, Medicherla S et al.. Role of TGF-{beta}/ALK5 kinase in monocrotaline-induced pulmonary hypertension.  Am J Respir Crit Care Med. 2008;  177 896-905
  CrossrefPubMedGoogle Scholar
• 82 Runo J R, Vnencak-Jones C L, Prince M et al.. Pulmonary veno-occlusive disease caused by an inherited mutation in bone morphogenetic protein receptor II.  Am J Respir Crit Care Med. 2003;  167 889-894
  CrossrefPubMedGoogle Scholar
• 83 Montani D, Achouh L, Dorfmüller P et al.. Pulmonary veno-occlusive disease: clinical, functional, radiologic, and hemodynamic characteristics and outcome of 24 cases confirmed by histology.  Medicine (Baltimore). 2008;  87 220-233
  CrossrefPubMedGoogle Scholar
• 84 Simonneau G, Galiè N, Rubin L J et al.. Clinical classification of pulmonary hypertension.  J Am Coll Cardiol. 2004;  43(12, Suppl S) 5S-12S
  CrossrefPubMedGoogle Scholar
• 85 Abenhaim L, Moride Y, Brenot F International Primary Pulmonary Hypertension Study Group et al. Appetite-suppressant drugs and the risk of primary pulmonary hypertension.  N Engl J Med. 1996;  335 609-616
  CrossrefPubMedGoogle Scholar
• 86 Sztrymf B, Yaïci A, Jaïs X, Sitbon O, Simonneau G, Humbert M. Idiopathic pulmonary hypertension: what did we learn from genes?.  Sarcoidosis Vasc Diffuse Lung Dis. 2005;  22(Suppl 1) S91-S100
  PubMedGoogle Scholar
• 87 Roberts K E, McElroy J J, Wong W P et al.. BMPR2 mutations in pulmonary arterial hypertension with congenital heart disease.  Eur Respir J. 2004;  24 371-374
  CrossrefPubMedGoogle Scholar
• 88 Rubin L J. BMPR2 mutation and outcome in pulmonary arterial hypertension: clinical relevance to physicians and patients.  Am J Respir Crit Care Med. 2008;  177 1300-1301
  CrossrefPubMedGoogle Scholar
• 89 McGoon M, Gutterman D, Steen V American College of Chest Physicians et al. Screening, early detection, and diagnosis of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines.  Chest. 2004;  126(1, Suppl) 14S-34S
  CrossrefPubMedGoogle Scholar
• 90 Jones D L, Sandberg J C, Rosenthal M J, Saunders R C, Hannig V L, Clayton E W. What patients and their relatives think about testing for BMPR2.  J Genet Couns. 2008;  17 452-458
  CrossrefPubMedGoogle Scholar
• 91 Grünig E, Dehnert C, Mereles D et al.. Enhanced hypoxic pulmonary vasoconstriction in families of adults or children with idiopathic pulmonary arterial hypertension.  Chest. 2005;  128(6, Suppl) 630S-633S
  PubMedGoogle Scholar

James E LoydM.D. 

Department of Medicine, Division of Pulmonary, Allergy, and Critical Care Medicine

1161 21st Ave. South, T-1218 MCN, Vanderbilt University School of Medicine, Nashville, TN 37232-2578

Email: Jim.loyd@vanderbilt.edu